TransMedics Group enters the final stretch before its July 31 earnings report with short sellers in control, the stock down 10% on the week, and a Street consensus that still sees the shares at roughly double the current price.
The short interest story here is genuinely consequential. Nearly 23% of the free float is sold short — a level that has been broadly stable for weeks but ticked up 5% over the past five days to reach 7.84 million shares. That creeping build happened into price weakness, meaning shorts are not covering into the decline. FINRA's most recent fortnightly settlement figure put short shares at 7.68 million with days-to-cover at 7.2, which at current volumes implies over a week to unwind. The borrow market itself remains relatively unconstrained: availability is running at 113% — meaning there are still more shares available to lend than are currently borrowed — and cost to borrow, though jumping 32% on the week, is still only 0.6%. The setup says shorts are rebuilding and can do so cheaply.
Options positioning adds a different colour. Call demand is actually running above its recent norm — the put/call ratio has eased to 0.56, a notch below its 20-day average of 0.62, and nearly a full standard deviation through that average toward the bullish side. That divergence is worth flagging directly: while short sellers are adding exposure on the way down, options traders are not hedging aggressively. The put/call has trended steadily lower from readings near 0.77 in early June, which suggests at least some participants are positioning for a recovery into earnings rather than bracing for further downside.
The Street's bull case and the current price tell the most interesting story. The mean analyst price target is $117, implying 76% upside from the $66.42 close. Both TD Cowen (target $120, reiterated July 1) and Canaccord Genuity (target $124, maintained June 30) held their Buy ratings without flinching after this week's slide. Stifel, the lone Hold, actually raised its target to $80 from $75 in mid-June. The broad direction of travel from the May 6 post-earnings reset — when targets were slashed across the board from the $130–$190 range — was decisive, but the more recent actions all suggest the Street has found a floor on conviction. Bulls point to the underpenetrated organ care market and a projected 40% growth trajectory in the OrganOx division; bears note the risk of OPO market disruption and margin compression from ongoing SG&A and R&D investment. The ORTEX short score of 71.9, which has been grinding higher for two weeks, sits in the 4th percentile of the universe — a signal that the data-driven short case remains firmly intact.
The insider picture is one-sided but not alarming. The only trade in the past 90 days was a director sell of 9,624 shares at $75.06 in mid-June, worth roughly $722,000 — routine in size and executed before the current leg lower. Earlier in the year, CFO Hernandez sold at prices between $139 and $147, well above where the stock trades now. There has been no insider buying to offset the accumulated selling pressure since the stock's peak.
History from the last major earnings print is difficult to ignore. The May 5 Q1 report produced a one-day drop of 24.9% and a five-day loss of 34%. That single event reset the entire analyst target structure. The next print on July 31 therefore becomes a binary moment: the short interest at 23% of float and a 7.2-day cover ratio means any positive surprise carries meaningful squeeze potential, while another miss could test whether the Street's consensus targets hold their ground or reset again.
The July 31 earnings date is what frames everything — how borrow availability, short positioning, and options activity evolve over the next four weeks will be the clearest indicator of where conviction sits heading into that catalyst.
See the live data behind this article on ORTEX.
Open TMDX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
